Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double...
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
About this item
Full title
Author / Creator
Wu, Jiong , Jiang, Zefei , Liu, Zhenzhen , Yang, Benlong , Yang, Hongjian , Tang, Jinhai , Wang, Kun , Liu, Yunjiang , Wang, Haibo , Fu, Peifen , Zhang, Shuqun , Liu, Qiang , Wang, Shusen , Huang, Jian , Wang, Chuan , Wang, Shu , Wang, Yongsheng , Zhen, Linlin , Zhu, Xiaoyu , Wu, Fei , Lin, Xiang and Zou, Jianjun
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine has survival benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer. We further assessed addition of pyrotinib to trastuzumab and docetaxel in the neoadjuvant setting.
In this multicenter, double-blind, phase 3 study (PHEDRA), treatment-naive w...
Alternative Titles
Full title
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d032fcc84aa544e0b0ed2042112d1d40
Other Identifiers
ISSN
1741-7015
E-ISSN
1741-7015
DOI
10.1186/s12916-022-02708-3
